Accessibility Menu
Helix BioPharma logo

Helix BioPharma(OTC) HBPCF

Market Cap$130.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-87%
5 Year-51%
1 Year+185%
1 Month+0%
$1.71
+0%
+0.00Today
Helix BioPharma last closing stock price
MetricPriceDate
Last closeUSD 1.712026-07-02
Helix BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.712026-06-22
1 month+0%USD 1.712026-05-18
3 month-1.16%USD 1.732026-03-20
Year to date-1.37%USD 1.732025-12-12
1 year+185%USD 0.602025-06-12
3 year+135.86%USD 0.732023-05-17
5 year-51.02%USD 3.492021-06-28
Since inception-87.24%USD 13.402010-09-24

Helix BioPharma Financials at a Glance

Market Cap

$130.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$3.37M

EPS (TTM)

-$0.03

P/E Ratio

-53.61

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.71

Volume

20

Open

$1.71

Previous Close

$1.71

Daily Range

$1.71 - $1.71

52-Week Range

$0.60 - $1.73

Estimated Earnings Date

Jun 17, 2026

HBPCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Helix BioPharma

Helix BioPharma Corp. is a Canadian biotechnology company focused on immuno-oncology. The company is dedicated to developing innovative therapies for cancer treatment, particularly through its drug candidates L-DOS47 and V-DOS47.

Products and Services
  • L-DOS47 targets non-small cell lung cancer
  • V-DOS47 interacts with vascular epithelial growth factor receptor 2 (VEGFR2)
  • Collaborative research with Moffitt Cancer Center and University Hospital Tuebingen
Growth Outlook
  • Partnerships with leading cancer research institutions enhance development capabilities
  • Focus on innovative therapies positions the company in a growing market
  • Research advancements may lead to significant breakthroughs in cancer treatment
Financial Highlights
  • Recent quarterly net income of -$670,777 reflects ongoing R&D investments
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Cash and cash equivalents of $2,841,059 provide operational runway for future projects
Helix BioPharma Corp. is actively engaged in the development of novel cancer therapies, with a strong emphasis on immuno-oncology. The company's lead candidates, L-DOS47 and V-DOS47, are designed to address significant unmet needs in cancer treatment. Collaborative agreements with prestigious institutions like Moffitt Cancer Center and University Hospital Tuebingen underscore the commitment to advancing research and development efforts. Despite the current lack of revenue, the company is strategically positioned within a growing market, focusing on innovative solutions that could lead to substantial breakthroughs in cancer care. The recent financial data indicates a continued investment in research and development, which is essential for long-term growth. With a solid cash position, Helix BioPharma Corp. is poised to navigate the challenges of the biotechnology landscape while pursuing its mission to improve cancer treatment outcomes.
AI Generated • Jul 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7

CEO

Thomas Mehrling, MD, PhD

Website

www.helixbiopharma.com

Headquarters

Toronto, ON M5H 2Y4, CA

HBPCF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-21.54%

Return on Capital

-31.58%

Return on Assets

-15.54%

Earnings Yield

-1.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$130.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

76.38M

Volume

20

Avg. Volume

18.065

Financials (TTM)

Gross Profit

-CA$4.15K

Operating Income

-CA$3.32M

EBITDA

-CA$1.71M

Operating Cash Flow

-CA$3.21M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$3.21M

Cash & ST Invst.

CA$2.84M

Total Debt

CA$358.88K

Helix BioPharma Performance Analysis

Helix BioPharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31CAD 0N/A
20232023-07-31CAD 0N/A
20242024-07-31CAD 0N/A
20252025-07-31CAD 0N/A
Helix BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31N/A
Q12025-10-31N/A
Q22026-01-31N/A
Q32026-04-30N/A
Helix BioPharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31CAD -0.17-24.4%
20232023-07-31CAD -0.12-29.8%
20242024-07-31CAD -0.1526.3%
20252025-07-31CAD -0.07-56.3%
Helix BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-3194.2%
Q12025-10-31-44.6%
Q22026-01-3131.6%
Q32026-04-303.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$999.00

+54.0%

Gross Margin

0.00%

N/A

Market Cap

$130.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$18.66M

N/A

Employees

7

N/A

Net Income

-CA$670.78K

+56.6%

EBITDA

-CA$688.77K

+55.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$2.84M

+297.4%

Total Debt

CA$358.88K

N/A

Accounts Receivable

CA$27.99K

-90.2%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$358.88K

N/A

Return on Assets

-15.54%

N/A

Return on Invested Capital

-22.47%

N/A

Free Cash Flow

-CA$879.71K

+36.3%

Operating Cash Flow

-CA$879.71K

+36.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INNMFAmplia Therapeutics Limited
$0.11+0.00%
VICPVicapsys Life Sciences, Inc.
$1.46+0.00%
ACHFFArch Biopartners Inc.
$0.58+4.90%
ZIVOZIVO Bioscience, Inc.
$5.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.23+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About HBPCF

What is the current price of Helix BioPharma?

Helix BioPharma is trading at $1.71 per share.

What is the 52-week range for Helix BioPharma?

Over the past 52 weeks, Helix BioPharma has traded between $0.60 and $1.73.

How much debt does Helix BioPharma have?

As of the most recent reporting period, Helix BioPharma reported total debt of CA$263.76K.

How much cash does Helix BioPharma have on hand?

Helix BioPharma reported CA$2.09M in cash and cash equivalents in its most recent financial results.

What is Helix BioPharma’s dividend yield?

Helix BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services